AVEO Oncology’s Fotivda (tivozanib) Receives the US FDA’s Approval for the Treatment of R/R Advanced Renal Cell Carcinoma

 AVEO Oncology’s Fotivda (tivozanib) Receives the US FDA’s Approval for the Treatment of R/R Advanced Renal Cell Carcinoma

BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma

Shots:

  • The approval is based on a P-III TIVO-3 study that involves assessing Fotivda (1.34 mg/qd, with or without food for 21days followed by 7days off treatment) vs sorafenib in 350 patients in a ratio (1:1) with r/r advanced RCC following two or more prior systemic therapies.
  • The application is also supported by three additional trials in RCC and includes safety data from 1,000+ trial subjects. The P-III TIVO-3 study results: mPFS (5.6 vs 3.9mos.), m-OS (16.4 vs 19.2mos.), ORR (18% vs 8%).
  • Fotivda (tivozanib, qd, PO) is a VEGF tyrosine kinase inhibitor and is available to patients in the US by Mar 31, 2021

Click here to­ read full press release/ article | Ref: Business Wire | Image: AVEO Oncology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post